Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Given the accelerating sales growth of LIBTAYO and stabilization in the EYLEA franchise, investors bid up the price of Regeneron's stock by +4.5% on Tuesday. The company's robust performance makes ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

and Libtayo, two other drugs in Regeneron's lineup. These changes reflect a nuanced view of the company's potential revenue streams. The $200 reduction in the price target for Regeneron primarily ...